SciVision Biotech Return On Asset vs. Price To Book

1786 Stock  TWD 94.30  0.40  0.42%   
Considering the key profitability indicators obtained from SciVision Biotech's historical financial statements, SciVision Biotech may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess SciVision Biotech's ability to earn profits and add value for shareholders.
For SciVision Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of SciVision Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well SciVision Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between SciVision Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of SciVision Biotech over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between SciVision Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if SciVision Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SciVision Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

SciVision Biotech Price To Book vs. Return On Asset Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining SciVision Biotech's current stock value. Our valuation model uses many indicators to compare SciVision Biotech value to that of its competitors to determine the firm's financial worth.
SciVision Biotech is number one stock in return on asset category among its peers. It also is number one stock in price to book category among its peers fabricating about  74.63  of Price To Book per Return On Asset. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SciVision Biotech's earnings, one of the primary drivers of an investment's value.

SciVision Price To Book vs. Return On Asset

Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

SciVision Biotech

Return On Asset

 = 

Net Income

Total Assets

 = 
0.0331
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

SciVision Biotech

P/B

 = 

MV Per Share

BV Per Share

 = 
2.47 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

SciVision Price To Book Comparison

SciVision Biotech is currently under evaluation in price to book category among its peers.

SciVision Biotech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in SciVision Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, SciVision Biotech will eventually generate negative long term returns. The profitability progress is the general direction of SciVision Biotech's change in net profit over the period of time. It can combine multiple indicators of SciVision Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. SciVision Biotech Inc.was founded in 2001 and is based in Kaohsiung, Taiwan. SCIVISION BIOTECH operates under Medical Instruments Supplies classification in Taiwan and is traded on Taiwan Stock Exchange.

SciVision Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on SciVision Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of SciVision Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the SciVision Biotech's important profitability drivers and their relationship over time.

Use SciVision Biotech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SciVision Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SciVision Biotech will appreciate offsetting losses from the drop in the long position's value.

SciVision Biotech Pair Trading

SciVision Biotech Pair Trading Analysis

The ability to find closely correlated positions to SciVision Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SciVision Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SciVision Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SciVision Biotech to buy it.
The correlation of SciVision Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SciVision Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SciVision Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SciVision Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your SciVision Biotech position

In addition to having SciVision Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Trump Equities Thematic Idea Now

Trump Equities
Trump Equities Theme
Stocks that have significantly increased in valuation since Trump was elected president of the United States. The Trump Equities theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Trump Equities Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for SciVision Stock Analysis

When running SciVision Biotech's price analysis, check to measure SciVision Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SciVision Biotech is operating at the current time. Most of SciVision Biotech's value examination focuses on studying past and present price action to predict the probability of SciVision Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SciVision Biotech's price. Additionally, you may evaluate how the addition of SciVision Biotech to your portfolios can decrease your overall portfolio volatility.